Allegro Integrin Peptide Therapy is an intravitreal injection designed to treat diseases such as macular degeneration and diabetic macular edema.
Senju will pay Allegro an upfront license fee, a percentage of royalty sales and sales milestone fees in exchange for the right to co-develop and market the peptide therapy in Japan.
More Articles on Ophthalmology:
Anschutz Investment Donates $.15M to Create Ophthalmology Chair at CU
FDA Approves Bausch + Lomb TRULIGN Astigmatism Correction Lens
NIVISON, Avellino Labs Partner to Offer Patients ACD Testing
